Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zealand Pharma
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent obtained before any trial-related activity
Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial (ZP1848-15073)
You may not be if
Withdrawal of consent from the lead-in trial
Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results
Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening
Females of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective contraceptive methods
